BioSpace News Archive

Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, announced positive interim results from its clinical study.

Invitation to attend Vitrolife’s conference call regarding presentation of the Report on Operations 2020.

FDA recognizes importance of increased availability of devices such as market leading TEG® hemostasis analyzers

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for oral, once-daily ORLADEYO ™ (berotralstat) 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. ORLADEYO is the first and only prophylactic HAE medication approved in Japan.

Elekta AB announced that it has sold its 7.3 percent of the outstanding common stock in ViewRay, Inc. Elekta has no remaining shares in ViewRay after the transaction..

The Montreal Heart Institute announced that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19.

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval of its fourth-generation Vercise Genus™ Deep Brain Stimulation (DBS) System.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of the ZENITH20 clinical trial. In addition, Spectrum also announced an oral presentation on the structural classification of atypical EGFR mutations and their patterns of drug sensitivity.

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that interim data from the Phase 1b/2 EQUATE study of itolizumab in acute graft-versus-host disease (aGVHD) has been accepted as a late-breaking oral presentation at the 2021 TCT Meetings Digital Experience, being held February 8-12, 2021.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the release of its inaugural ESG Report, which details the company’s commitments and efforts to build strong corporate governance, and operate sustainably and responsibly, including its response to the COVID-19 pandemic and prevailing social issues in 2020.